论文部分内容阅读
目的探讨口服布洛芬混悬液治疗新生儿动脉导管未闭(PDA)的临床疗效。方法选择经心脏彩超确诊的53例PDA新生儿随机分成两组,治疗组27例,于出生后2~7 d分3次口服布洛芬混悬液治疗。结果治疗组动脉导管关闭率明显高于对照组,但两组相比χ2=2.621,P>0.05,差异无统计学意义。其中布洛芬混悬液治疗后足月儿动脉导管关闭率稍高于早产儿,但差异无统计学意义(P>0.05)。用药期间血清尿素氮和肌酐含量正常。结论口服布洛芬混悬液治疗新生儿动脉导管未闭,疗效好,且不良反应小。
Objective To investigate the clinical efficacy of oral ibuprofen suspension in the treatment of neonatal patent ductus arteriosus (PDA). Methods Fifty-three newborns with PDA diagnosed by echocardiography were randomly divided into two groups. The treatment group (n = 27) received oral ibuprofen suspension three to seven days after birth. Results The rate of patent ductus arteriosus closure in the treatment group was significantly higher than that in the control group, but there was no significant difference between the two groups (χ2 = 2.621, P> 0.05). Among them, the close rate of full-term infantile arterial catheter was slightly higher than that of premature infants after ibuprofen suspension treatment, but the difference was not statistically significant (P> 0.05). Serum urea nitrogen and creatinine levels during treatment were normal. Conclusion Oral ibuprofen suspension treatment of patent ductus arteriosus in neonates with good curative effect and small adverse reactions.